Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Cassava Sciences, Inc. - Common Stock (NQ:SAVA)

2.160 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
37 38 Next >
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Why Shares of Cassava Sciences Jumped This Week
Cassava Sciences finished dosing in one of its phase 3 trials for its Alzheimer's therapy Simufilam. 
Via The Motley Fool
Cassava Sciences Completes Patient Dosing in a Randomized Controlled Trial of Simufilam in Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
Top 5 Health Care Stocks That May Collapse In Q2
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Why Is Cassava Sciences (SAVA) Stock Up 15% Today?
Today, shareholders in Cassava Sciences and SAVA stock are cheering some positive research data for its key drug candidate. 
Via InvestorPlace
3 Big Reasons to Sell Cassava Sciences Stock Right Now
It isn't about running out of money, but it's still laden with risk. 
Via The Motley Fool
If You Invested $100 In This Stock 5 Years Ago, You Would Have $400 Today
 
Via Benzinga
Why Is Cassava Sciences (SAVA) Stock Down 20% Today?
Here's why shares of Cassava Sciences and SAVA stock are on the decline today, amid a relatively calm day overall. 
Via InvestorPlace
New Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin A
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences to Present at the 2023 H.C. Wainwright Investor Conference
From Cassava Sciences, Inc.
Via GlobeNewswire
Short Interest Sector Focus: Healthcare Sector
As of the close of business on Monday, 3/31, we captured the Top 10 Highest Short Interest % stocks within the Healthcare sector. The average short interest for stocks within the Healthcare sector... 
Via Benzinga
Why Is Asana (ASAN) Stock Up 24% Today?
Asana (ASAN) stock is on the rise Thursday as investors react to the CEO share purchase plans and its latest earnings report. 
Via InvestorPlace
ETSY Stock Falls on Double Downgrade
Etsy (ETSY) stock is falling on Thursday after the e-commerce company's shares were hit with a double downgrade from Jefferies. 
Via InvestorPlace
3 Short-Squeeze Stocks to Keep on Your Radar
These three short-squeeze stocks are each options investors may want to consider as companies with near-term catalysts that could run. 
Via InvestorPlace
Insider Richard Barry Is Betting Big on Cassava (SAVA) Stock
Any Alzheimer's drug that worked would be an instant blockbuster, but science doesn't work on an investor's schedule. 
Via InvestorPlace
Why Cassava Sciences Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Tesla, Apple, Cassava Sciences, MongoDB, Asana: Why These Five Stocks Are Drawing Investors' Attention Today?
 
Via Benzinga
Why Cassava Sciences Stock Is Surging After Hours
Cassava Sciences Inc (NASDAQ: SAVA) shares are rising in extended trading Wednesday in the wake of recent insider buying.  
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates
From Cassava Sciences, Inc.
Via GlobeNewswire
3 Drug Stocks to Watch as Alzheimer’s Clinical Trials End
These drug companies are running clinical trials for Alzheimer's drugs. The cure is worth billions, so these are the drug stocks to watch. 
Via InvestorPlace
Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
From Cassava Sciences, Inc.
Via GlobeNewswire
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a 
Via MarketBeat
Tesla, Amazon, Microsoft, Cassava Sciences, Intuitive Surgical: Why These 5 Stocks Are Drawing Investors' Attention Today
Major Wall Street indices closed mixed on Tuesday as a disparate set of corporate earnings dampened the existing euphoria over the possibility of a slowdown in rate hikes. 
Via Benzinga
Cassava Sciences Stock Is Diving: What's Going On?
Cassava Sciences Inc (NASDAQ: SAVA) shares are trading significantly lower Tuesday after the company announced top-line clinical results from a Phase 2 study 
Via Benzinga
Why Baudax Bio Shares Are Trading Higher By 60%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Baudax Bio, Inc. (NASDAQ: BXRX) shares surged 59.7% to $5.03 after the company announced the outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade in... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Cassava Sciences Shares Fall As Alzheimer's Candidate Worsens Patients With Moderate Disease
 
Via Benzinga
Cassava Plummets As 'Highly Desirable' Alzheimer's Results Don't Cut It With Investors
Some patients improved while taking the company's twice-daily pill. 
Via Investor's Business Daily
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
37 38 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.